To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Denmark’s Novo Nordisk to acquire venture-backed Inversago Pharma
Inversago is a Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and other serious metabolic disorders.
